
Shares of Emergent BioSolutions EBS.N fall 12.5% to $5.98 in extended trading, the lowest since September
Company reported a decline in its fourth-quarter revenue, which stood at $194.7 million, down from $276.6 million a year ago
On an adjusted basis, company reported EPS of 5 cents, vs a loss of 77 cents previous year
Company is moving forward with turnaround activities, a critical phase in its multi-year transformation plan - EBS
Company's shares up 298.3% in 2024